Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Harrah Chiang"'
Autor:
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc7b96d8807b2e71c6f5c425780ec51
https://doi.org/10.1158/1078-0432.22467627
https://doi.org/10.1158/1078-0432.22467627
Autor:
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom
Supplemental Figure 1. Glesatinib is a potent and selective MET inhibitor. Supplemental Figure 2. Waterfall plot of glesatinib activity across pre-clinical tumor models. Supplemental Figure 3. SNU-638 Criz-res line is homogeneous and harbors the F120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c375882160e71f15fa4df153bf834a2
https://doi.org/10.1158/1078-0432.22467621.v1
https://doi.org/10.1158/1078-0432.22467621.v1
Autor:
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom
Purpose: MET exon 14 deletion (METex14 del) mutations represent a novel class of non–small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a spectrum-selective MET inhibitor exhibiting a type II binding mode, in METex14 del–po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bf6bc9e9872b1b6f95da5a8da32f467
https://doi.org/10.1158/1078-0432.c.6526698.v1
https://doi.org/10.1158/1078-0432.c.6526698.v1
Autor:
David James Stephen, David S Axford, Harrah Chiang, Paul Brisson, Benjamin D Harman, Michael Brisson, Tayler Gant
Publikováno v:
Cureus
Background There is evidence to suggest that early exposure to clinical experiences could bolster a medical student's education and prepare them to tackle the problem-based learning encountered during clinical rotations. We hypothesized that incorpor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22608bfce5d0c71ebc2a8bb1e82dd65a
https://doi.org/10.7759/cureus.13966
https://doi.org/10.7759/cureus.13966
Autor:
Jay B, Fell, John P, Fischer, Brian R, Baer, James F, Blake, Karyn, Bouhana, David M, Briere, Karin D, Brown, Laurence E, Burgess, Aaron C, Burns, Michael R, Burkard, Harrah, Chiang, Mark J, Chicarelli, Adam W, Cook, John J, Gaudino, Jill, Hallin, Lauren, Hanson, Dylan P, Hartley, Erik J, Hicken, Gary P, Hingorani, Ronald J, Hinklin, Macedonio J, Mejia, Peter, Olson, Jennifer N, Otten, Susan P, Rhodes, Martha E, Rodriguez, Pavel, Savechenkov, Darin J, Smith, Niranjan, Sudhakar, Francis X, Sullivan, Tony P, Tang, Guy P, Vigers, Lance, Wollenberg, James G, Christensen, Matthew A, Marx
Publikováno v:
Journal of medicinal chemistry. 63(13)
Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc99717000ce420f505732f20b4224e4
https://pubmed.ncbi.nlm.nih.gov/32250617
https://pubmed.ncbi.nlm.nih.gov/32250617
Autor:
Joshua Ballard, Harrah Chiang, James G. Christensen, Kenneth Hee, Tony Pisal Tang, Brian R. Baer, Peter Olson, Henry J. Zecca, David Briere, Mark Joseph Chicarelli, Laurence E. Burgess, Karyn Bouhana, Jill Hallin, Matthew A. Marx, Lauren Hanson, Barbara J. Brandhuber, Michael Burkard, Fell Jay Bradford, Pavel Savechenkov, James F. Blake, John P. Fischer, Guy Vigers, Hicken Erik James, Niranjan Sudhakar, Kevin Davidson, Ronald Jay Hinklin, Macedonio J. Mejia, John Gaudino
Publikováno v:
ACS Medicinal Chemistry Letters. 9:1230-1234
[Image: see text] KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly associated with poor prognosis and resistance to standard treatment. The ability to effectively target and block the function of mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a511b6ef25dc7584d5aa3f9ed4d78a97
https://doi.org/10.1021/acsmedchemlett.8b00382
https://doi.org/10.1021/acsmedchemlett.8b00382
Autor:
Jeffrey S. Weber, Ruth Aranda, Andressa L. Sodre, David Briere, Peter Olson, David M. Woods, Jill Hallin, James G. Christensen, Harrah Chiang, Lars D. Engstrom, Niranjan Sudhakar
Publikováno v:
Cancer Immunology, Immunotherapy. 67:381-392
Checkpoint inhibitor therapy has led to major treatment advances for several cancers including non-small cell lung cancer (NSCLC). Despite this, a significant percentage of patients do not respond or develop resistance. Potential mechanisms of resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39d4029cd09ce22f08423bc3fa47d21d
https://doi.org/10.1007/s00262-017-2091-y
https://doi.org/10.1007/s00262-017-2091-y
Autor:
Jill Hallin, Lyudmilla Bazhenova, James G. Christensen, Natalia Baños, Richard C. Chao, Camino Menéndez, Mark M. Awad, Nir Peled, Mizuki Nishino, Peter Olson, V. Tassell, Richard B. Lanman, Geoffrey I. Shapiro, Matthew Randolf Lee, Lars D. Engstrom, Zachary Madaj, Sandip Pravin Patel, Manuel Hidalgo, Ruth Aranda, Carrie R. Graveel, Pasi A. Jänne, David Briere, Elizabeth A. Tovar, Curt J. Essenburg, Harrah Chiang, Pedro P. López-Casas, Darya Chudova
Publikováno v:
Clinical Cancer Research. 23:6661-6672
Purpose: MET exon 14 deletion (METex14 del) mutations represent a novel class of non–small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a spectrum-selective MET inhibitor exhibiting a type II binding mode, in METex14 del–po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f832c15c470a03d975226964ccfecffd
https://doi.org/10.1158/1078-0432.ccr-17-1192
https://doi.org/10.1158/1078-0432.ccr-17-1192
Autor:
James G. Christensen, Macedonia J. Mejia, Tony Pisal Tang, Joshua Ballard, Pavel Y. Savechenkov, Mark Joseph Chicarelli, Guy Vigers, Niranjan Sudhakar, James F. Blake, Peter D. Olson, Brian R. Baer, David Briere, Matthew A. Marx, Fell Jay Bradford, Michael R. Burkhard, Karyn Bouhana, Laurence E. Burgess, Jill Hallin, Harrah Chiang, John P. Fischer
Publikováno v:
Molecular Cancer Research. 18:B30-B30
The ability to effectively target mutated KRAS has remained elusive despite decades of research. By solving a highly informative set of ligand-complexed co-crystal structures coupled with iterative structure-based drug design, substituted tetrahydrop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6886a9bb95b32c7a7f0ea987f77aeeb5
https://doi.org/10.1158/1557-3125.ras18-b30
https://doi.org/10.1158/1557-3125.ras18-b30
Autor:
David Briere, Lauren Hargis, James G. Christensen, Matthew A. Marx, Jill Hallin, Fell Jay Bradford, Lars D. Engstrom, Niranjan Sudhakar, Peter D. Olson, Andrew Calinisan, Michael R. Burkhard, John P. Fischer, Harrah Chiang, Ruth Aranda, Brian R. Baer
Publikováno v:
Molecular Cancer Research. 18:B23-B23
KRAS G12C is a driver mutation and the most frequent KRAS mutation in lung cancer. The ability to effectively target mutated KRAS has remained elusive despite decades of research. A structure-based drug design discovery program identified mutant-sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1be8c7bdc37581e0db27049ad22395d1
https://doi.org/10.1158/1557-3125.ras18-b23
https://doi.org/10.1158/1557-3125.ras18-b23